FI760884A - - Google Patents

Info

Publication number: FI760884A
Authority: FI; Finland

Application number

FI760884A

Other languages

Finnish (fi)

Other versions

FI62087B (fi

FI62087C (fi

Inventor

Willem Jacob Van Der Burg

Original Assignee

Akzo Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-04-05

Filing date

1976-04-01

Publication date

1976-10-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI760884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1976-04-01 Application filed by Akzo Nv filed Critical Akzo Nv

1976-10-06 Publication of FI760884A publication Critical patent/FI760884A/fi

1982-07-30 Publication of FI62087B publication Critical patent/FI62087B/fi

1982-11-10 Application granted granted Critical

1982-11-10 Publication of FI62087C publication Critical patent/FI62087C/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

FI760884A 1975-04-05 1976-04-01 Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet FI62087C (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL7504075		1975-04-05
NLAANVRAGE7504075,A NL189199C (nl)	1975-04-05	1975-04-05	Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Publications (3)

Publication Number	Publication Date
FI760884A true FI760884A (fr)	1976-10-06
FI62087B FI62087B (fi)	1982-07-30
FI62087C FI62087C (fi)	1982-11-10

Family

ID=19823518

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI760884A FI62087C (fi)	1975-04-05	1976-04-01	Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet

Country Status (17)

Country	Link
US (1)	US4062848A (fr)
JP (1)	JPS5942678B2 (fr)
BE (1)	BE840362A (fr)
CA (1)	CA1076571A (fr)
CH (1)	CH622261A5 (fr)
DE (1)	DE2614406A1 (fr)
DK (1)	DK142498B (fr)
ES (2)	ES446634A1 (fr)
FI (1)	FI62087C (fr)
FR (1)	FR2305986A1 (fr)
GB (1)	GB1543171A (fr)
HU (1)	HU179401B (fr)
IE (1)	IE42969B1 (fr)
LU (1)	LU74680A1 (fr)
NL (2)	NL189199C (fr)
SE (1)	SE422941B (fr)
ZA (1)	ZA761756B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4515792A (en) *	1982-09-30	1985-05-07	Ciba-Geigy Corporation	Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) *	1986-07-31	1988-02-17	Matsushita Electric Ind Co Ltd	カセツト方式文字放送受信機
JPS63177670A (ja) *	1987-01-31	1988-07-21	Fujitsu General Ltd	文字放送受信装置
JPS63215179A (ja) *	1987-03-03	1988-09-07	Fujitsu General Ltd	受信装置
JPH055746Y2 (fr) *	1988-04-27	1993-02-15
NO175781C (no) *	1989-10-05	1994-12-07	Sankyo Co	Analogifremgangsmåte for fremstilling av terapeutisk aktive tetracykliske forbindelser
EP0539164A1 (fr) *	1991-10-23	1993-04-28	Sankyo Company Limited	Composés tétracycliques contenant l'azote ayant des propriétés antiallergiques et antiasthmatiques, leur préparation et utilisation
IL121076A (en) *	1996-06-19	2000-10-31	Akzo Nobel Nv	Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
CA2326356C (fr) *	1998-04-02	2008-06-03	Akzo Nobel N.V.	Solution orale liquide exercant un effet antidepresseur
US6545149B2 (en)	1999-04-19	2003-04-08	Teva Pharmaceutical Industries Ltd.	Synthesis and crystallization of piperazine ring-containing compounds
SK14672001A3 (sk) *	1999-04-19	2002-11-06	Teva Pharmaceutical Industries Ltd.	Spôsob syntézy a kryštalizácie zlúčenín obsahujúcich piperazínový kruh
EP1178805A4 (fr) *	1999-04-19	2004-11-24	Teva Pharma	Nouvelle synthese et cristallisation de composes contenant de la piperazine
TR200103035T2 (tr)	1999-04-19	2002-01-21	Teva Pharmaceutical Industries Ltd.	Yeni piperazin halkası sentezi.
US6281207B1 (en) *	1999-09-15	2001-08-28	Reed Richter	Treatment of movement disorders by administration of mirtazapine
AU6476300A (en) *	1999-09-30	2001-05-10	Sumika Fine Chemicals Co., Ltd.	Process for the preparation of a piperazine derivative
WO2001038329A1 (fr) *	1999-11-24	2001-05-31	Sumika Fine Chemicals Co., Ltd.	Cristaux de mirtazapine anhydre et leur procede d'obtention
AU6474200A (en) *	1999-12-13	2001-06-18	Sumika Fine Chemicals Co., Ltd.	Process for the preparation of a pyridinemethanol compound
AU780817B2 (en) *	2000-01-19	2005-04-21	Akzo Nobel N.V.	Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
DE60117122T2 (de)	2000-02-11	2006-07-27	Akzo Nobel N.V.	Verwendung von mirtazapin zur behandlung von schlafstörungen
IN190478B (fr) *	2000-11-07	2003-08-02	Sun Pharmaceutical Ind Ltd
US6660730B2 (en) *	2000-11-27	2003-12-09	Sumika Fine Chemicals Co., Ltd.	Anhydrous mirtazapine and process for preparing the same
US6399310B1 (en)	2001-02-12	2002-06-04	Akzo Nobel N.V.	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
AU2002237847A1 (en) *	2001-02-12	2002-08-28	Akzo Nobel N.V	Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US20030105082A1 (en) *	2001-12-03	2003-06-05	Murphy Greer Marechal	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
IL157607A0 (en)	2001-03-01	2004-03-28	Teva Pharma	Methods for the preparation of mirtazapine intermediates
US7355042B2 (en) *	2001-10-16	2008-04-08	Hypnion, Inc.	Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) *	2002-10-03	2006-08-16	Zentiva, A.S.	Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
US20040192754A1 (en) *	2003-03-24	2004-09-30	Shapira Nathan Andrew	Methods for treating idiopathic hyperhidrosis and associated conditions
UA83666C2 (ru) *	2003-07-10	2008-08-11	Н.В. Органон	Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) *	2003-07-31	2010-11-23	Watson Laboratories, Inc.	Mirtazapine solid dosage forms
TW200538100A (en) *	2004-04-21	2005-12-01	Akzo Nobel Nv	Mirtazapine salts
EP1753460A2 (fr) *	2004-05-11	2007-02-21	Pfizer Products Inc.	Combinaison d'antipsychotiques atypiques et d'antagonistes du recepteur de 5-ht1b
EP1776160A1 (fr) *	2004-08-13	2007-04-25	Omeros Corporation	Nouveaux ligands de recepteur de serotonine et leurs utilisations
WO2006023702A2 (fr) *	2004-08-20	2006-03-02	Cypress Bioscience, Inc.	Methode de traitement de troubles respiratoires lies au sommeil a l'aide de setiptiline
JP4848704B2 (ja) *	2004-08-24	2011-12-28	住友化学株式会社	２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法
EP1783125A4 (fr) *	2004-08-24	2008-06-18	Sumitomo Chemical Co	Methode de production de 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopyridine
TW200631584A (en) *	2004-11-15	2006-09-16	Akzo Nobel Nv	A medicament related to mirtazapine for the treatment of hot flush
EP1827450A4 (fr) *	2004-11-17	2009-04-22	Cypress Bioscience Inc	Methodes servant a limiter les effets secondaires d'un traitement par mirtazapine
US20090306046A1 (en) *	2005-06-27	2009-12-10	N.V. Organon	Method of treatment of hormone depletion induced vasomotor symptoms
EP1904843A2 (fr)	2005-07-08	2008-04-02	Braincells, Inc.	Methodes destinees a identifier des agents et des conditions modulant la neurogenese
CN1939918B (zh) *	2005-09-30	2010-09-01	北京德众万全医药科技有限公司	一种米氮平的制备方法
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20070225217A1 (en)	2005-11-09	2007-09-27	Combinatorx, Incorporated	Methods, compositions, and kits for the treatment of medical conditions
ZA200804860B (en) *	2005-11-14	2009-11-25	Sumitomo Chemical Co	Method for producing 2-(4-methyl-2-phenylpiperazin-1-yl)pyridine-3-methanol
EP1792618A1 (fr)	2005-11-30	2007-06-06	Rainer Freynhagen	R-mirtazapine pour le traitement de la douleur
WO2007101832A1 (fr) *	2006-03-06	2007-09-13	N.V. Organon	Méthode perfectionnée pour sevrer d'un traitement hormonal de symptômes vasomoteurs induits par un épuisement hormonal
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (fr)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenèse par modulation de l'angiotensine
US7858611B2 (en) *	2006-05-09	2010-12-28	Braincells Inc.	Neurogenesis by modulating angiotensin
MX2008014320A (es)	2006-05-09	2009-03-25	Braincells Inc	Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20070270413A1 (en) *	2006-05-22	2007-11-22	N.V. Organon	Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) *	2006-06-16	2008-04-01	Organon Nv	Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
MX2009002496A (es) *	2006-09-08	2009-07-10	Braincells Inc	Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20080167363A1 (en) *	2006-12-28	2008-07-10	Braincells, Inc	Modulation of Neurogenesis By Melatoninergic Agents
CA2675132A1 (fr) *	2007-01-11	2008-07-17	Braincells, Inc.	Modulation de la neurogenese en utilisant du modafinil
JP5192707B2 (ja) *	2007-03-22	2013-05-08	住友化学株式会社	ミルタザピンの製造方法
US7994314B2 (en) *	2007-04-11	2011-08-09	N.V. Organon	Method for the preparation of an enantiomerically pure benzazepine
JP5635905B2 (ja) *	2007-04-11	2014-12-03	メルク・シャープ・エンド・ドーム・ベー・フェー	ミルタザピンの調製方法
MX2009010964A (es) *	2007-04-11	2009-10-30	Organon Nv	Un metodo para la preparacion de una benzazepina enantiomericamente pura.
US20080255348A1 (en) *	2007-04-11	2008-10-16	N.V. Organon	Method for the preparation of an enantiomer of a tetracyclic benzazepine
EP2167096A4 (fr) *	2007-06-13	2010-07-14	Cypress Bioscience Inc	Amélioration de la tolérance à la mirtazapine et à un second principe actif par utilisation combinée de ces derniers
JP2009018992A (ja) *	2007-07-10	2009-01-29	Sumitomo Chemical Co Ltd	光学活性ミルタザピンの製造方法
EP2288345B1 (fr)	2008-04-18	2015-06-10	University College Dublin National University Of Ireland, Dublin	Produits psycho-pharmaceutiques
EP2291181B9 (fr)	2008-04-18	2013-09-11	University College Dublin National University Of Ireland, Dublin	Utilisation de la captodiamine pour le traitement des symptômes de la dépression
CA2727573A1 (fr) *	2008-06-25	2009-12-30	Pfizer Inc.	Composes diaryle et leurs utilisations
US20110201804A1 (en) *	2008-10-22	2011-08-18	Watson Pharma Private Limited	Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
CN102432594B (zh) *	2011-11-28	2013-09-11	山东鲁药制药有限公司	一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) *	2013-10-21	2014-01-15	山东鲁药制药有限公司	一种米氮平的合成方法
CN104356133A (zh) *	2014-11-25	2015-02-18	南京工业大学	一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) *	2015-02-20	2018-12-05	株式会社トクヤマ	１−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法
KR102540021B1 (ko)	2020-12-02	2023-06-07	(주)유케이케미팜	대량 생산에 적합한 미르타자핀의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL129434C (fr) *	1966-03-12
NL7202963A (fr) *	1972-03-07	1973-09-11
US3959470A (en) *	1972-11-28	1976-05-25	Mikhail Davidovich Mashkovsky	Psychotropic medicinal preparation

1975
- 1975-04-05 NL NLAANVRAGE7504075,A patent/NL189199C/xx not_active IP Right Cessation
1976
- 1976-03-23 US US05/669,544 patent/US4062848A/en not_active Expired - Lifetime
- 1976-03-23 ZA ZA761756A patent/ZA761756B/xx unknown
- 1976-03-23 IE IE614/76A patent/IE42969B1/en unknown
- 1976-03-26 GB GB12270/76A patent/GB1543171A/en not_active Expired
- 1976-03-29 CH CH388676A patent/CH622261A5/de not_active IP Right Cessation
- 1976-03-30 DK DK142676AA patent/DK142498B/da active Protection Beyond IP Right Term
- 1976-04-01 FI FI760884A patent/FI62087C/fi not_active IP Right Cessation
- 1976-04-02 CA CA249,439A patent/CA1076571A/fr not_active Expired
- 1976-04-02 JP JP51037678A patent/JPS5942678B2/ja not_active Expired
- 1976-04-02 DE DE19762614406 patent/DE2614406A1/de active Granted
- 1976-04-02 SE SE7603931A patent/SE422941B/xx active Protection Beyond IP Right Term
- 1976-04-02 LU LU74680A patent/LU74680A1/xx unknown
- 1976-04-02 ES ES446634A patent/ES446634A1/es not_active Expired
- 1976-04-02 BE BE165832A patent/BE840362A/fr not_active IP Right Cessation
- 1976-04-02 FR FR7609686A patent/FR2305986A1/fr active Granted
- 1976-04-05 HU HU76AO437A patent/HU179401B/hu unknown
1977
- 1977-05-31 ES ES459348A patent/ES459348A1/es not_active Expired
1994
- 1994-04-21 NL NL940007C patent/NL940007I2/nl unknown

Also Published As

Publication number	Publication date
LU74680A1 (fr)	1976-11-11
NL940007I2 (nl)	1994-10-17
FR2305986A1 (fr)	1976-10-29
IE42969B1 (en)	1980-11-19
NL189199C (nl)	1993-02-01
NL7504075A (nl)	1976-10-07
DE2614406C2 (fr)	1992-02-20
JPS5942678B2 (ja)	1984-10-16
FI62087B (fi)	1982-07-30
SE422941B (sv)	1982-04-05
NL940007I1 (nl)	1994-06-01
US4062848A (en)	1977-12-13
GB1543171A (en)	1979-03-28
FI62087C (fi)	1982-11-10
AU1236176A (en)	1977-09-29
IE42969L (en)	1976-10-05
NL189199B (nl)	1992-09-01
DK142498B (da)	1980-11-10
CA1076571A (fr)	1980-04-29
ES446634A1 (es)	1977-11-01
JPS51122099A (en)	1976-10-25
DK142676A (fr)	1976-10-06
CH622261A5 (fr)	1981-03-31
HU179401B (en)	1982-10-28
DE2614406A1 (de)	1976-10-14
ES459348A1 (es)	1978-03-16
ZA761756B (en)	1977-03-30
SE7603931L (sv)	1976-10-06
DK142498C (fr)	1981-07-06
FR2305986B1 (fr)	1980-06-13
BE840362A (fr)	1976-10-04

Publication	Publication Date	Title
FI760884A (fr)	1976-10-06
JPS5198854U (fr)	1976-08-07
CH590507B5 (fr)	1977-08-15
BG22875A1 (fr)	1977-05-20
BG21822A1 (fr)	1976-09-20
BG22146A1 (fr)	1977-05-20
BG22183A1 (fr)	1977-02-20
BG22299A1 (fr)	1977-02-20
BG22302A1 (fr)	1977-02-20
BG22453A1 (fr)	1977-04-20
BG22641A1 (fr)	1977-04-20
CH592775B5 (fr)	1977-11-15
BG21649A1 (fr)	1976-09-20
BG22898A1 (fr)	1977-05-20
BG22977A1 (fr)	1977-05-20
CH1667075A4 (fr)	1977-08-31
CH584449A5 (fr)	1977-01-31
CH586353A5 (fr)	1977-02-15
CH587716A5 (fr)	1977-05-13
CH588069A5 (fr)	1977-05-31
CH601710A5 (fr)	1978-07-14
CH588643A5 (fr)	1977-06-15
CH589911A5 (fr)	1977-07-29
CH602912A5 (fr)	1978-08-15
BG21771A1 (fr)	1977-05-20

Legal Events

Date	Code	Title	Description
1976-04-01	MA	Patent expired
1996-01-18	ND	Supplementary protection certificate (spc) granted
1996-01-18	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: L60 Extension date: 20010401
2004-08-31	MA	Patent expired	Owner name: AKZO N.V.